Loading...

ANNOUNCEMENT : InnoPharm 2025
Share:

From Lab to Life: The Future of PK/PD with Global Pioneer Prof. Leslie Benet

By: Gayatri Srinivas
Conference Manager, InnoPharm 2025
05/06/2025

Prof. Leslie Z. Benet to Deliver Plenary Lecture on Advanced PK/PD Concepts Driving Drug Innovation

Capitol Building

We are thrilled to announce Prof. Leslie Z. Benet, Professor Emeritus of Bioengineering and Therapeutic Sciences at the University of California, San Francisco (UCSF), as a Plenary Speaker at InnoPharm-2025.

With a career spanning more than five decades, Prof. Benet is globally recognized as one of the foundational architects of modern pharmacokinetics (PK) and pharmacodynamics (PD). He is best known for his work on drug metabolism, bioequivalence, and the Biopharmaceutics Drug Disposition Classification System (BDDCS), which is now widely adopted in drug regulatory and development frameworks.

At InnoPharm-2025, Prof. Benet will present his talk titled:
“New Concepts in Pharmacokinetics and Pharmacodynamics that Facilitate Drug Development”

This session will explore how innovative PK/PD models are revolutionizing early-stage drug design, improving prediction accuracy, and accelerating regulatory approval processes. His insights will be critical for scientists, clinicians, and industry professionals navigating the challenges of modern drug development.

Why It Matters:

In a time when drug pipelines are becoming more complex and precision medicine is taking center stage, Prof. Benet’s work offers a scientific and regulatory bridge to streamline discovery-to-approval timelines. His presentation will also touch upon real-world applications of BDDCS, transporter-enzyme interplay, and bioequivalence standards—making this a must-attend session for anyone invested in the future of pharma.

About Prof. Benet:

  • Published over 600 peer-reviewed articles
  • Recipient of multiple lifetime achievement awards, including from AAPS, FIP, and ACCP
  • Member of the National Academy of Medicine
  • Mentored over 150 PhDs and postdoctoral scholars
  • Co-founder of the first clinical pharmacokinetics journal